From Seekingalpha · Justin Miller · · 40s
Moderna Stock Hype Over Cancer Vaccine
Moderna's cancer vaccine stock price far exceeds fair value, demanding Keytruda-scale success.
In brief
Moderna's cancer vaccine stock price far exceeds fair value, demanding Keytruda-scale success. Moderna's stock price is priced at $69B peak sales for intismeran despite first approval unlikely before 2027. Originally reported by Seekingalpha.
Moderna Stock Rating
Moderna is rated Sell as the stock price far exceeds even the most bullish fair value estimates.
Valuation Implications
MRNA's valuation implies $69B in peak sales for intismeran despite the company only owning half.
Timeline for Approval
First approval for intismeran is unlikely before 2027.
Market Expectations
The market is pricing in a perfect outcome yet pivotal Phase 3 hazard ratio data remains undisclosed.
At a glance
Moderna's stock price is priced at $69B peak sales for intismeran despite first approval unlikely before 2027.
